Navigation Links
DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA Therapeutics S.A. an emerging pharmaceutical company specialized in innovative cancer therapy announces today the elucidation of a new mechanism of action and the identification of a biomarker of its first-in-class antitumoral lead molecule Dbait. It will be presented at the forecoming American Association for Cancer Research annual meeting 2007. Its abstract is now available online. The presentation itself will be available from April 16th onwards at http://www.dna-therapeutics.com/doc/File/pdf/AACR2K7.pdf

Background: Most of the cancer therapies induce directly or indirectly DNA double strand breaks (DSBs), but unfortunately cells possess DNA repair complexes specialized in repairing these lethal lesions, which are responsible of lessened efficacy, or refractoriness of classical therapies.

A new family of anticancer drugs, named short inhibiting DNA (siDNA), has been designed by DNA Therapeutics' scientific founder team to inhibit these repair activities. The first lead, named Dbait, mimics DSBs, diverts DSB repair system from their primary objective, and facilitates cancer cells killing by traditional therapies.

The proof of concept work was presented last November at the 18th EORTC-NCI-AACR Symposium "Molecular Targets and Cancer Therapeutics" (Prague): the median survival of nude mice grafted with human tumor cell lines treated by intra-tumoral injection of Dbait, in association with radiotherapy, is significantly increased in a dose-dependent manner. MRI and cytology analysis of tumors shows that Dbait strongly enhances irradiation-induced necrosis and apoptosis.

New finding: The present study aims at deciphering the underlying mechanism of action of Dbait at molecular and cellular levels, and in particular its impact on DSB repair foci organi zation at chromatin level.

It is known that the kinases ATM/ATR and DNA-PK are involved in the general cellular response to DNA damage by signaling proteins that control cell cycle, apoptosis and DNA repair. In particular, ATM and DNA-PK both phosphorylate the H2AX, an isoform of the histone H2A, after exposure to ionizing radiation. The appearance of the phosphorylated H2AX, called gamma-H2AX, in cell nuclei is an indicator of DSB repair foci.

Our data provides evidence that Dbait specifically activates DNA-PK but not ATM kinase activity, as the phosphorylation of H2AX is in a DNA-PK dependent manner. Dbait-induced H2AX phosphorylation persists more than 6 days as compared to 1 day for irradiation. Cell imaging shows that the global distribution of gamma-H2AX in the nucleus of the cells transfected by Dbait was radically different of the gamma-H2AX foci organization observed when H2AX phosphorylation was triggered by irradiation alone. This indicates that DSB repair system is dramatically disorganized in Dbait transfected cells, and points out a new mechanism of action.

In addition, the amount of gamma-H2AX is proportional to that of Dbait in cultured cells and in the cells from tumor samples. gamma-H2AX appears to be a specific biomarker of Dbait in cells. It can be easily used to monitor the bioactivity of Dbait molecules in further preclinical and clinical development.

M. Dutreix who conducted this study said "this additional mechanism of antitumoral action of Dbait molecules confirms that the use of Dbait which baits, hijacks the enzyme complexes that repair DSBs and disorganizes DSB repair system, is a novel and attractive pathway-targeting approach in molecular cancer therapy".

J.S. Sun, CEO of DNA Therapeutics comments "The elucidation of Dbait's mechanisms of action and the identification of gamma-H2AX as a specific biomarker of Dbait activity are important milestones of DNA Therapeutics' development". He adds "DNA Therape utics is currently raising series A to finance regulatory preclinical, and phase I/IIb trial anticipated to be initiated in Q4 2008".

About DNA Therapeutics: http://www.dna-therapeutics.com

DNA Therapeutics S.A., founded in May 2006, as a spinoff from the Institut Curie, the CNRS, the INSERM (French NIH) and the Museum National d'Histoire Naturelle, is the premier corporation developing DNA baits to trap enzyme complexes involved in DNA repair and inhibit their DNA repair capacity, as an innovative approach to enhance conventional anticancer therapy. It is headquartered in the Genopole Biocluster (Evry, France). DNA Therapeutics is being granted a portfolio of worldwide exclusive license from the parent institutions on DNA bait and related technologies.

    Contacts:


    Pr. Jian-Sheng Sun, Ph.D.

    Chairman and CEO

    Phone: +33-624-753-239

    Email: 


sun@dna-therapeutics.com

CONTACT: Contacts: Pr. Jian-Sheng Sun, Ph.D., Chairman and CEO, Phone:+33-624-753-239, Email: sun@dna-therapeutics.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... FRANCISCO , February 9, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, ... be a featured presenting company at Source Capital Group,s ... on February 10-11, 2016 in New York ... on Wednesday, February 10, 2016 at 12:30 pm by ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... ... 09, 2016 , ... Ross A. Clevens, MD, FACS ... welcome a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, ... practitioner performing cosmetic procedures including injectables, fillers and laser treatments. A ...
Breaking Medicine News(10 mins):